[
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma - Slideshow",
    "summary": "2025-12-16. The following slide deck was published by Regeneron Pharmaceuticals, Inc.",
    "url": "https://finnhub.io/api/news?id=64d36f6260f9ecc139cc0c3581cda066cc10cc2f0f12d6cbefc6cc271d1e2b4f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765908316,
      "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma - Slideshow",
      "id": 137805147,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "2025-12-16. The following slide deck was published by Regeneron Pharmaceuticals, Inc.",
      "url": "https://finnhub.io/api/news?id=64d36f6260f9ecc139cc0c3581cda066cc10cc2f0f12d6cbefc6cc271d1e2b4f"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Adds to Its Big Bet on Weight Loss Drugs",
    "summary": "A month after acquiring obesity biotech Metsera, Pfizer's expanding in the weight loss drug market after signing a licensing agreement for a weight loss pill.",
    "url": "https://finnhub.io/api/news?id=0bf50c3ab54a5bdda61d0957c5bf307e8eb784f93f7a05e00a85977e902c81da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765886580,
      "headline": "Pfizer Adds to Its Big Bet on Weight Loss Drugs",
      "id": 137816786,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "A month after acquiring obesity biotech Metsera, Pfizer's expanding in the weight loss drug market after signing a licensing agreement for a weight loss pill.",
      "url": "https://finnhub.io/api/news?id=0bf50c3ab54a5bdda61d0957c5bf307e8eb784f93f7a05e00a85977e902c81da"
    }
  },
  {
    "ts": null,
    "headline": "2 Large-Cap Stocks on Our Buy List and 1 We Find Risky",
    "summary": "Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.",
    "url": "https://finnhub.io/api/news?id=a9c3edeb13ba2deca2b689169cca820cfc356aaa144f195548d1068a1c281f9e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765859745,
      "headline": "2 Large-Cap Stocks on Our Buy List and 1 We Find Risky",
      "id": 137806328,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.",
      "url": "https://finnhub.io/api/news?id=a9c3edeb13ba2deca2b689169cca820cfc356aaa144f195548d1068a1c281f9e"
    }
  }
]